PTGX
Income statement / Annual
Last year (2025), Protagonist Therapeutics Inc's total revenue was $46.02 M,
a decrease of 89.41% from the previous year.
In 2025, Protagonist Therapeutics Inc's net income was -$130.15 M.
See Protagonist Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$46.02 M |
$434.43 M |
$60.00 M |
$26.58 M |
$27.36 M |
$28.63 M |
$231.00 K |
$30.93 M |
$20.06 M |
$0.00 |
| Cost of Revenue |
$1.23 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$317.00 K
|
| Gross Profit |
$44.79 M
|
$434.43 M
|
$60.00 M
|
$26.58 M
|
$27.36 M
|
$28.63 M
|
$231.00 K
|
$30.93 M
|
$20.06 M
|
-$317.00 K
|
| Gross Profit Ratio |
0.97
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$159.29 M
|
$138.13 M
|
$120.16 M
|
$126.22 M
|
$126.01 M
|
$75.98 M
|
$65.00 M
|
$59.50 M
|
$46.18 M
|
$25.71 M
|
| General & Administrative Expenses |
$44.85 M
|
$43.46 M
|
$33.49 M
|
$31.74 M
|
$27.20 M
|
$18.64 M
|
$15.75 M
|
$13.70 M
|
$11.78 M
|
$6.96 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$44.85 M
|
$43.46 M
|
$33.49 M
|
$31.74 M
|
$27.20 M
|
$18.64 M
|
$15.75 M
|
$13.70 M
|
$11.78 M
|
$6.96 M
|
| Other Expenses |
-$1.23 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.48 M
|
-$1.00 K
|
$0.00
|
$0.00
|
-$34.00 K
|
| Operating Expenses |
$202.92 M
|
$181.59 M
|
$153.65 M
|
$157.95 M
|
$153.20 M
|
$93.14 M
|
$80.75 M
|
$73.19 M
|
$57.96 M
|
$32.67 M
|
| Cost And Expenses |
$204.14 M
|
$181.59 M
|
$153.65 M
|
$157.95 M
|
$153.20 M
|
$93.14 M
|
$80.75 M
|
$73.19 M
|
$57.96 M
|
$32.67 M
|
| Interest Income |
$28.79 M
|
$26.32 M
|
$14.90 M
|
$4.06 M
|
$443.00 K
|
$900.00 K
|
$2.81 M
|
$2.57 M
|
$948.00 K
|
$242.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$598.00 K
|
$169.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.23 M
|
$826.00 K
|
$3.31 M
|
$3.37 M
|
$2.78 M
|
$948.00 K
|
$703.00 K
|
$527.00 K
|
$406.00 K
|
$317.00 K
|
| EBITDA |
-$128.09 M |
$280.23 M |
-$75.64 M |
-$124.02 M |
-$122.78 M |
-$63.57 M |
-$77.01 M |
-$39.20 M |
-$36.55 M |
-$32.35 M |
| EBITDA Ratio |
-2.78
|
0.65
|
-1.26
|
-4.67
|
-4.49
|
-2.22
|
-333.36
|
-1.27
|
-1.82
|
0
|
| Operating Income Ratio |
-3.44
|
0.58
|
-1.56
|
-4.94
|
-4.6
|
-2.25
|
-348.58
|
-1.37
|
-1.89
|
0
|
| Total Other Income/Expenses Net |
$28.82 M
|
$26.57 M
|
$14.70 M
|
$3.98 M
|
$294.00 K
|
-$329.00 K
|
$2.64 M
|
$2.55 M
|
$940.00 K
|
-$4.51 M
|
| Income Before Tax |
-$129.31 M
|
$279.41 M
|
-$78.96 M
|
-$127.39 M
|
-$125.55 M
|
-$64.85 M
|
-$77.88 M
|
-$39.72 M
|
-$36.96 M
|
-$37.18 M
|
| Income Before Tax Ratio |
-2.81
|
0.64
|
-1.32
|
-4.79
|
-4.59
|
-2.27
|
-337.13
|
-1.28
|
-1.84
|
0
|
| Income Tax Expense |
$838.00 K
|
$4.22 M
|
$0.00
|
$0.00
|
$0.00
|
$1.31 M
|
-$691.00 K
|
-$799.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$130.15 M
|
$275.19 M
|
-$78.96 M
|
-$127.39 M
|
-$125.55 M
|
-$66.15 M
|
-$77.19 M
|
-$38.92 M
|
-$36.96 M
|
-$37.18 M
|
| Net Income Ratio |
-2.83
|
0.63
|
-1.32
|
-4.79
|
-4.59
|
-2.31
|
-334.14
|
-1.26
|
-1.84
|
0
|
| EPS |
-2.05 |
4.47 |
-1.39 |
-2.52 |
-2.65 |
-1.92 |
-2.98 |
-1.74 |
-2.09 |
-5.72 |
| EPS Diluted |
-2.05 |
4.23 |
-1.39 |
-2.52 |
-2.65 |
-1.92 |
-2.98 |
-1.74 |
-2.09 |
-5.72 |
| Weighted Average Shares Out |
$63.57 M
|
$61.57 M
|
$56.76 M
|
$49.04 M
|
$46.32 M
|
$34.40 M
|
$25.89 M
|
$22.36 M
|
$17.69 M
|
$6.50 M
|
| Weighted Average Shares Out Diluted |
$63.57 M
|
$65.08 M
|
$56.76 M
|
$49.04 M
|
$46.32 M
|
$34.40 M
|
$25.89 M
|
$22.36 M
|
$17.69 M
|
$6.50 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
